Chronic Internal Carotid Artery Occlusion
Conditions
Interventions
Test group:The test group was treated with endovascular therapy plus active drug therapy.
Control group:The control group was actively treated with medication
Sponsors
Guangdong Second Provincial General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old; 2. Symptomatic onset within 12 months prior to randomization, manifested as transient ischemic attack (TIA), non-disabling or mild-to-moderate stroke in the area of responsible vascular blood supply (subject's modified Rankin scale (mRS) score at randomization =1 time) or the presence of abnormal perfusion in the responsible vascular blood supply area confirmed by CTP (MTT>4s, rCBF<0.95); 6. The patient or legal representative is able to understand the purpose of the trial, voluntarily participate in and sign a written informed consent form, and is able to accept regular follow-up.
Exclusion criteria
Exclusion criteria: 1. Previous history of cerebral hemorrhage, and/or large cerebral infarction (infarct volume > 70ml or infarct area greater than 1/3 of the middle cerebral artery blood supply area); 2. Known presence of an aneurysm in the ipsilateral intracranial segment of the occluded internal carotid artery; 3. Previous definite myocardial infarction or severe heart failure (NYHA cardiac function class III./IV.); 4. Presence of active bleeding, severe anemia, coagulation dysfunction (presence of at least one of the following laboratory tests: hemoglobin 1.5, PT >1 minute above the upper limit of normal, or heparin-related thrombocytopenia); 5. Gastrointestinal or urinary hemorrhage, head injury or major surgery in the past 1 month; 6. Ipsilateral vascular prior interventions such as stent implantation, balloon dilation, or coil tamponade; 7. Imaging abnormalities with severe vascular flexure or anatomical, extensive or diffuse atherosclerotic disease involving the aortic arch and proximal common carotid artery, etc., which in the opinion of the investigator is expected to be unable to complete the operation; 8. Allergy to any contrast agent or device related to endovascular treatment or other contraindications to cerebral angiography; 9. Severe concomitant diseases with poor prognosis (life expectancy < 2 years); 10. Females known to be pregnant or lactating; 11. Unwilling to accept randomized selection of treatment regimens, unable to understand and cooperate with study procedures or provide informed consent; 12. Participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of composite endpoint events of stroke or death within 30 days after randomization or ipsilateral ischemic stroke from 30 days to 2 years later.;Endovascular treatment of complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of any stroke within 2 years of randomization;Incidence of all disabling strokes within 2 years of randomization;Incidence of all fatal strokes within 2 years of randomization;Incidence of any death within 2 years of randomization;Incidence of any stroke and death within 2 years of randomization;The score of the Modified Rankin Scale;National Institute of Health stroke scale; | — |
Countries
China
Contacts
Public ContactZhixin Huang
Guangdong Second Provincial General Hospital
Outcome results
None listed